Academic Student Training Consultation for Urology, Technical University Dresden, Dresden, Germany.
Joint Office of the Clinical Cancer Registries in Saxony, The State Chamber of Physicians of Saxony, Dresden, Germany.
Urol Int. 2022;106(7):706-715. doi: 10.1159/000519210. Epub 2021 Oct 26.
The aim of this study was to assess penile cancer incidence, clinical characteristics, treatment options, transparency of clinical quality, and relative survival based on data from the clinical cancer registry.
A total of 898 patients with tumours of the penis were diagnosed and analysed in the period from 2000 to 2018; they were documented in the 4 regional clinical cancer registries and summarized in the Command Office of these 4 registries.
The standardized incidence rate increased from 0.86 in 2000 to 2.67 in 2018. Most tumours were located at the glans (42.9%) followed by the prepuce (19.5%) and corpus penis (6.9%); they were classified into pT1a/pT1b (20.0%/7.0%), pT2 (23.5%), pT3 (12.4%), and pT4 (0.8%). In only 32.0% of all documented cases, a stage-related lymphadenectomy (LND) was carried out. Negative surgical margins were found in only 70% and the Rx status in 15.1%. Primary metastasis was detected in pN1 (5.1%), pN2 (3.9%), pN3 (3.1%), and M1 status in 3.0%, respectively. The predominant therapy was surgery in 78.3%. The proportion of penile partial resections was significantly (p = 0.0045) regredient over the control period. Adjuvant chemotherapy was performed in 4.7%, adjuvant external-beam radiotherapy in 3.0%. The 5-year relative overall survival rate was 74.7% and ranged from 108.0% (stage 0) to 17.1% (stage IV). A total of 29 hospitals performed tumour operations.
The multitude of clinical and epidemiological variables available in clinical cancer registries allows a safe assessment of tumour dynamics themselves, as well as good quality of transparency and broadly acceptable guideline adherence. Deviations from the accepted level of evidence were found in the grading definition, in the high quota of positive surgical margins, in the defensive indication position to the glans resurfacing/reconstruction and diagnostical LND. Based on these relevant findings in the database combined with the low frequency of the tumour in area/clinics/year, we recommended establishing SCCP reference clinics. This work is the first time that European standardized rate-based cancer registry data on penile cancer from Germany has been communicated.
本研究旨在评估基于临床癌症登记数据的阴茎癌发病率、临床特征、治疗选择、临床质量透明度和相对生存率。
2000 年至 2018 年间,共有 898 例阴茎肿瘤患者被诊断并分析,这些患者被记录在 4 个区域性临床癌症登记处,并汇总在这 4 个登记处的指挥办公室。
标准化发病率从 2000 年的 0.86 上升到 2018 年的 2.67。大多数肿瘤位于龟头(42.9%),其次是包皮(19.5%)和阴茎体(6.9%);它们被分为 pT1a/pT1b(20.0%/7.0%)、pT2(23.5%)、pT3(12.4%)和 pT4(0.8%)。在所有记录的病例中,只有 32.0%进行了与分期相关的淋巴结清扫术(LND)。仅 70%的病例切缘阴性,Rx 状态为 15.1%。pN1(5.1%)、pN2(3.9%)、pN3(3.1%)和 M1 状态分别发现原发性转移。主要治疗方法是手术,占 78.3%。阴茎部分切除术的比例在整个对照期间呈显著下降趋势(p = 0.0045)。辅助化疗占 4.7%,辅助外照射放疗占 3.0%。5 年相对总生存率为 74.7%,范围从 108.0%(0 期)到 17.1%(IV 期)。共有 29 家医院进行了肿瘤手术。
临床癌症登记处提供的大量临床和流行病学变量可安全评估肿瘤动态本身,以及良好的透明度和广泛可接受的指南遵循情况。在分级定义、高比例阳性切缘、对龟头表面重建/修复和诊断性 LND 的防御性适应证方面存在偏离公认证据水平的情况。基于数据库中的这些相关发现,再结合该肿瘤在地区/诊所/年的低频率,我们建议建立 SCCP 参考诊所。这是首次报道德国基于欧洲标准化率的阴茎癌癌症登记数据。